1,2-dimethylhydrazine increases expression ISO RGD:1322854 6480464 1, 2-Dimethylhydrazine results in increased expression of GPR183 mRNA CTD PMID:22206623 17beta-estradiol increases expression ISO RGD:1346200 6480464 Estradiol results in increased expression of GPR183 mRNA CTD PMID:31614463 2,2',4,4'-Tetrabromodiphenyl ether decreases expression ISO RGD:1346200 6480464 2 more ... CTD PMID:19095052 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1322854 6480464 [TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of GPR183 mRNA CTD PMID:25975270 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of GPR183 mRNA CTD PMID:34747641 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1322854 6480464 Tetrachlorodibenzodioxin results in increased expression of GPR183 mRNA CTD PMID:26290441 2-hydroxypropanoic acid increases expression ISO RGD:1346200 6480464 Lactic Acid results in increased expression of GPR183 mRNA CTD PMID:30851411 4-hydroxynon-2-enal increases expression ISO RGD:1322854 6480464 4-hydroxy-2-nonenal results in increased expression of GPR183 mRNA CTD PMID:19191707 4-hydroxyphenyl retinamide decreases expression ISO RGD:1322854 6480464 Fenretinide results in decreased expression of GPR183 mRNA CTD PMID:28973697 acetamide increases expression EXP 6480464 acetamide results in increased expression of GPR183 mRNA CTD PMID:31881176 albendazole multiple interactions ISO RGD:1346200 6480464 [Ivermectin co-treated with Albendazole] results in decreased expression of GPR183 mRNA CTD PMID:16861626 antirheumatic drug decreases expression ISO RGD:1346200 6480464 Antirheumatic Agents results in decreased expression of GPR183 mRNA CTD PMID:24449571 arotinoid acid multiple interactions ISO RGD:1346200 6480464 [4-(2-(5 more ... CTD PMID:34480604 arsenous acid increases expression ISO RGD:1346200 6480464 Arsenic Trioxide results in increased expression of GPR183 mRNA CTD PMID:15761015 benzo[a]pyrene increases expression ISO RGD:1346200 6480464 Benzo(a)pyrene results in increased expression of GPR183 mRNA CTD PMID:20064835 benzo[a]pyrene multiple interactions ISO RGD:1322854 6480464 AHR protein affects the reaction [Benzo(a)pyrene affects the expression of GPR183 mRNA], Benzo(a)pyrene promotes the reaction [AHR protein binds to GPR183 promoter] CTD PMID:19654925 , PMID:22228805 benzo[a]pyrene decreases methylation ISO RGD:1346200 6480464 Benzo(a)pyrene results in decreased methylation of GPR183 5' UTR, Benzo(a)pyrene results in decreased methylation of GPR183 promoter CTD PMID:27901495 benzo[a]pyrene increases methylation ISO RGD:1322854 6480464 Benzo(a)pyrene results in increased methylation of GPR183 3' UTR, Benzo(a)pyrene results in increased methylation of GPR183 exon CTD PMID:27901495 benzo[a]pyrene decreases expression ISO RGD:1322854 6480464 Benzo(a)pyrene results in decreased expression of GPR183 mRNA CTD PMID:21569818 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of GPR183 mRNA CTD PMID:25181051 , PMID:34947998 bisphenol A multiple interactions ISO RGD:1346200 6480464 [bisphenol A co-treated with Fulvestrant] results in decreased methylation of GPR183 gene CTD PMID:31601247 bisphenol A affects methylation ISO RGD:1346200 6480464 bisphenol A affects the methylation of GPR183 gene CTD PMID:31601247 buta-1,3-diene decreases expression ISO RGD:1322854 6480464 1, 3-butadiene results in decreased expression of GPR183 mRNA CTD PMID:29038090 butyric acid decreases expression ISO RGD:1346200 6480464 Butyric Acid results in decreased expression of GPR183 mRNA CTD PMID:33770205 cadmium atom multiple interactions ISO RGD:1346200 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of GPR183 mRNA CTD PMID:35301059 cadmium dichloride multiple interactions ISO RGD:1346200 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of GPR183 mRNA CTD PMID:35301059 cannabidiol decreases expression ISO RGD:1322854 6480464 Cannabidiol results in decreased expression of GPR183 mRNA CTD PMID:21542829 carbon nanotube increases expression ISO RGD:1322854 6480464 Nanotubes, Carbon results in increased expression of GPR183 mRNA CTD PMID:25554681 carbon nanotube decreases expression ISO RGD:1322854 6480464 Nanotubes, Carbon results in decreased expression of GPR183 mRNA CTD PMID:25926378 CHIR 99021 multiple interactions ISO RGD:1346200 6480464 [4-(2-(5 more ... CTD PMID:34480604 chloroprene decreases expression ISO RGD:1322854 6480464 Chloroprene results in decreased expression of GPR183 mRNA CTD PMID:23125180 cisplatin increases expression ISO RGD:1346200 6480464 Cisplatin results in increased expression of GPR183 mRNA CTD PMID:27594783 cortisol multiple interactions ISO RGD:1346200 6480464 [4-(2-(5 more ... CTD PMID:34480604 crocidolite asbestos decreases expression ISO RGD:1322854 6480464 Asbestos, Crocidolite results in decreased expression of GPR183 mRNA CTD PMID:29279043 Cuprizon increases expression EXP 6480464 Cuprizone results in increased expression of GPR183 mRNA CTD PMID:27523638 diarsenic trioxide increases expression ISO RGD:1346200 6480464 Arsenic Trioxide results in increased expression of GPR183 mRNA CTD PMID:15761015 dimethylarsinic acid multiple interactions ISO RGD:1322854 6480464 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR183 mRNA CTD PMID:34876320 doxorubicin decreases expression ISO RGD:1346200 6480464 Doxorubicin results in decreased expression of GPR183 mRNA CTD PMID:29803840 entinostat decreases expression ISO RGD:1346200 6480464 entinostat results in decreased expression of GPR183 mRNA CTD PMID:33770205 ethyl methanesulfonate decreases expression ISO RGD:1346200 6480464 Ethyl Methanesulfonate results in decreased expression of GPR183 mRNA CTD PMID:23649840 ferric oxide increases expression ISO RGD:1322854 6480464 ferric oxide analog results in increased expression of GPR183 mRNA CTD PMID:24525745 fulvestrant multiple interactions ISO RGD:1346200 6480464 [bisphenol A co-treated with Fulvestrant] results in decreased methylation of GPR183 gene CTD PMID:31601247 furan increases expression EXP 6480464 furan results in increased expression of GPR183 mRNA CTD PMID:27387713 HC toxin decreases expression ISO RGD:1346200 6480464 HC toxin results in decreased expression of GPR183 mRNA CTD PMID:33770205 irinotecan increases expression ISO RGD:1346200 6480464 Irinotecan metabolite results in increased expression of GPR183 mRNA, Irinotecan results in increased expression of GPR183 mRNA CTD PMID:15956246 ivermectin multiple interactions ISO RGD:1346200 6480464 [Ivermectin co-treated with Albendazole] results in decreased expression of GPR183 mRNA CTD PMID:16861626 L-ascorbic acid multiple interactions ISO RGD:1346200 6480464 [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA CTD PMID:34480604 L-ascorbic acid 2-phosphate multiple interactions ISO RGD:1346200 6480464 [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA CTD PMID:34480604 lead diacetate increases expression EXP 6480464 lead acetate results in increased expression of GPR183 mRNA CTD PMID:22641619 lipopolysaccharide decreases expression ISO RGD:1322854 6480464 Lipopolysaccharides results in decreased expression of GPR183 mRNA CTD PMID:25890327 lipopolysaccharide multiple interactions ISO RGD:1346200 6480464 [S-(1 more ... CTD PMID:18192897 , PMID:35811015 methotrexate decreases expression ISO RGD:1346200 6480464 Methotrexate results in decreased expression of GPR183 mRNA CTD PMID:17400583 methyl methanesulfonate decreases expression ISO RGD:1346200 6480464 Methyl Methanesulfonate results in decreased expression of GPR183 mRNA CTD PMID:23649840 methylarsonic acid multiple interactions ISO RGD:1322854 6480464 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR183 mRNA CTD PMID:34876320 methylisothiazolinone increases expression ISO RGD:1346200 6480464 2-methyl-4-isothiazolin-3-one results in increased expression of GPR183 mRNA CTD PMID:31629900 Muraglitazar decreases expression EXP 6480464 muraglitazar results in decreased expression of GPR183 mRNA CTD PMID:21515302 nickel atom increases expression ISO RGD:1346200 6480464 Nickel results in increased expression of GPR183 mRNA CTD PMID:25583101 ozone multiple interactions ISO RGD:1322854 6480464 [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in decreased expression of GPR183 mRNA CTD PMID:34911549 panobinostat decreases expression ISO RGD:1346200 6480464 Panobinostat results in decreased expression of GPR183 mRNA CTD PMID:33770205 paracetamol affects expression ISO RGD:1322854 6480464 Acetaminophen affects the expression of GPR183 mRNA CTD PMID:17562736 pioglitazone decreases expression ISO RGD:1346200 6480464 Pioglitazone results in decreased expression of GPR183 mRNA CTD PMID:30031879 rac-lactic acid increases expression ISO RGD:1346200 6480464 Lactic Acid results in increased expression of GPR183 mRNA CTD PMID:30851411 rosuvastatin calcium multiple interactions ISO RGD:1346200 6480464 Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in increased expression of GPR183 mRNA] CTD PMID:18192897 rosuvastatin calcium increases expression ISO RGD:1346200 6480464 Rosuvastatin Calcium results in increased expression of GPR183 mRNA CTD PMID:18192897 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions ISO RGD:1346200 6480464 [S-(1 more ... CTD PMID:35811015 SB 431542 multiple interactions ISO RGD:1346200 6480464 [LDN 193189 co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with EGF protein co-treated with FGF2 protein] results in increased expression of GPR183 mRNA CTD PMID:34480604 sodium arsenate multiple interactions ISO RGD:1322854 6480464 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR183 mRNA CTD PMID:34876320 sodium arsenite multiple interactions ISO RGD:1322854 6480464 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR183 mRNA CTD PMID:34876320 sunitinib decreases expression ISO RGD:1346200 6480464 Sunitinib results in decreased expression of GPR183 mRNA CTD PMID:31533062 tacedinaline decreases expression ISO RGD:1346200 6480464 tacedinaline results in decreased expression of GPR183 mRNA CTD PMID:33770205 Tesaglitazar decreases expression EXP 6480464 tesaglitazar results in decreased expression of GPR183 mRNA CTD PMID:21515302 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of GPR183 mRNA CTD PMID:34492290 titanium dioxide increases expression EXP 6480464 titanium dioxide results in increased expression of GPR183 mRNA CTD PMID:30012374 trichloroethene decreases expression EXP 6480464 Trichloroethylene results in decreased expression of GPR183 mRNA CTD PMID:33387578 trichostatin A decreases expression ISO RGD:1346200 6480464 trichostatin A results in decreased expression of GPR183 mRNA CTD PMID:33770205 triclosan decreases expression ISO RGD:1346200 6480464 Triclosan results in decreased expression of GPR183 mRNA CTD PMID:30510588 trimellitic anhydride increases expression ISO RGD:1322854 6480464 trimellitic anhydride results in increased expression of GPR183 mRNA CTD PMID:19042947 troglitazone decreases expression EXP 6480464 troglitazone results in decreased expression of GPR183 mRNA CTD PMID:21515302 tunicamycin increases expression ISO RGD:1346200 6480464 Tunicamycin results in increased expression of GPR183 mRNA CTD PMID:33770205 valproic acid affects expression ISO RGD:1322854 6480464 Valproic Acid affects the expression of GPR183 mRNA CTD PMID:17963808 valproic acid decreases expression ISO RGD:1346200 6480464 Valproic Acid results in decreased expression of GPR183 mRNA CTD PMID:33770205 vorinostat decreases expression ISO RGD:1346200 6480464 Vorinostat results in decreased expression of GPR183 mRNA CTD PMID:33770205 XAV939 multiple interactions ISO RGD:1346200 6480464 [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA, [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA CTD PMID:34480604 zinc atom increases expression ISO RGD:1346200 6480464 Zinc deficiency results in increased expression of GPR183 mRNA CTD PMID:18356318 zinc(0) increases expression ISO RGD:1346200 6480464 Zinc deficiency results in increased expression of GPR183 mRNA CTD PMID:18356318